{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:26:22Z","timestamp":1791901582668,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671233"],"award-info":[{"award-number":["81671233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the discipline innovation and development plan of Tangdu Hospital-major program of clinical research","award":["2021LCYJ002"],"award-info":[{"award-number":["2021LCYJ002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40120-021-00292-x","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T19:01:03Z","timestamp":1635879663000},"page":"73-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Rong-Jing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Wu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Lan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-8017","authenticated-orcid":false,"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"292_CR1","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC. Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol. 2018;265:2773\u201382.","journal-title":"J Neurol"},{"key":"292_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010;41:379\u201384.","journal-title":"Muscle Nerve"},{"key":"292_CR3","first-page":"1","volume":"12","author":"M Li","year":"2019","unstructured":"Li M, Ge F, Guo R, Ruan Z. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1\u20138.","journal-title":"Ther Adv Neurol Disord"},{"key":"292_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS\/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687\u201393.","journal-title":"Eur J Neurol"},{"key":"292_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"YH Hong","year":"2008","unstructured":"Hong YH, Kwon SB, Kim BJ, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273:10\u20134.","journal-title":"J Neurol Sci"},{"key":"292_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015;122:1517\u201321.","journal-title":"Ophthalmology"},{"key":"292_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015;72:1170\u20134.","journal-title":"JAMA Neurol"},{"key":"292_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017;17:77.","journal-title":"BMC Neurol"},{"key":"292_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM. Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol. 2018;79:113\u20137.","journal-title":"Eur Neurol"},{"key":"292_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve. 2018;57:756\u201360.","journal-title":"Muscle Nerve"},{"key":"292_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"key":"292_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","volume":"209","author":"S Apinyawasisuk","year":"2020","unstructured":"Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S. Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol. 2020;209:10\u20137.","journal-title":"Am J Ophthalmol"},{"key":"292_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000507853","volume":"83","author":"X Feng","year":"2020","unstructured":"Feng X, Huan X, Yan C, et al. Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China. Eur Neurol. 2020;83:182\u20138.","journal-title":"Eur Neurol"},{"key":"292_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","volume":"20","author":"J Ding","year":"2020","unstructured":"Ding J, Zhao S, Ren K, et al. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China. BMC Neurol. 2020;20:238.","journal-title":"BMC Neurol"},{"key":"292_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT. Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. 2014;14:421.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"292_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","volume":"12","author":"JP Vandenbroucke","year":"2014","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500\u201324.","journal-title":"Int J Surg"},{"key":"292_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","volume":"21","author":"TH Popperud","year":"2017","unstructured":"Popperud TH, Boldingh MI, Rasmussen M, Kerty E. Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur J Paediatr Neurol. 2017;21:707\u201314.","journal-title":"Eur J Paediatr Neurol"},{"key":"292_CR18","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570\u201381.","journal-title":"N Engl J Med"},{"key":"292_CR19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/jama.2015.15281","volume":"314","author":"P Li","year":"2015","unstructured":"Li P, Stuart EA, Allison DB. Multiple imputation: a flexible tool for handling missing data. JAMA. 2015;314:1966\u20137.","journal-title":"JAMA"},{"key":"292_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018;128:15\u201324.","journal-title":"Int J Neurosci"},{"key":"292_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14:516\u20139.","journal-title":"Ann Neurol"},{"key":"292_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000500268","volume":"53","author":"P Maddison","year":"2019","unstructured":"Maddison P, Ambrose PA, Sadalage G, Vincent A. A prospective study of the incidence of myasthenia gravis in the East Midlands of England. Neuroepidemiology. 2019;53:93\u20139.","journal-title":"Neuroepidemiology"},{"key":"292_CR23","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063.","journal-title":"Lancet Reg Health West Pac"},{"key":"292_CR24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/WCO.0b013e32833c32af","volume":"23","author":"A Evoli","year":"2010","unstructured":"Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010;23:536\u201340.","journal-title":"Curr Opin Neurol"},{"key":"292_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","volume":"34","author":"X Huang","year":"2013","unstructured":"Huang X, Liu WB, Men LN, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci. 2013;34:911\u20137.","journal-title":"Neurol Sci"},{"key":"292_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"292_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Feng H, Chen P, Liu W. Clinical characteristics of juvenile myasthenia gravis in Southern China. Front Neurol. 2018;9:77.","journal-title":"Front Neurol"},{"key":"292_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243\u20138.","journal-title":"Arch Neurol"},{"key":"292_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"292_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","volume":"118","author":"G Galassi","year":"2018","unstructured":"Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118:435\u201343.","journal-title":"Acta Neurol Belg"},{"key":"292_CR31","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00415-020-10342-3","volume":"268","author":"G Monte","year":"2021","unstructured":"Monte G, Spagni G, Damato V, Iorio R, Marino M, Evoli A. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? J Neurol. 2021;268:1803\u20137.","journal-title":"J Neurol"},{"key":"292_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","volume":"36","author":"M Al-Haidar","year":"2018","unstructured":"Al-Haidar M, Benatar M, Kaminski HJ. Ocular myasthenia. Neurol Clin. 2018;36:241\u201351.","journal-title":"Neurol Clin"},{"key":"292_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1055\/s-0039-1700527","volume":"39","author":"M O'Hare","year":"2019","unstructured":"O\u2019Hare M, Doughty C. Update on ocular myasthenia gravis. Semin Neurol. 2019;39:749\u201360.","journal-title":"Semin Neurol"},{"key":"292_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12:259\u201368.","journal-title":"Nat Rev Neurol"},{"key":"292_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","volume":"49","author":"F Romi","year":"2017","unstructured":"Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol. 2017;49:9\u201313.","journal-title":"Curr Opin Immunol"},{"key":"292_CR36","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/ene.14036","volume":"26","author":"Y Geng","year":"2019","unstructured":"Geng Y, Dong J, Zhou Q. Rapid improvement of muscle weakness post-thymectomy indicates good long-term neurological outcome in patients with ocular myasthenia gravis. Eur J Neurol. 2019;26:1421\u20133.","journal-title":"Eur J Neurol"},{"key":"292_CR37","first-page":"373","volume":"15","author":"I Takanami","year":"2009","unstructured":"Takanami I, Abiko T, Koizumi S. Therapeutic outcomes in thymectomied patients with myasthenia gravis. Ann Thorac Cardiovasc Surg. 2009;15:373\u20137.","journal-title":"Ann Thorac Cardiovasc Surg"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00292-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00292-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T16:21:53Z","timestamp":1645201313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00292-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00292-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}